
From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD : Biotech companies race to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes ...
statnews.com/2026/07/28/biotech-industry-race-aatd-cure-gene-editing-alpha-1-antitrypsin-deficiency/

Paid articlePaywall Gene-editing startup launches with $230 million and a Chinese licensing deal: Serapha Bio is entering a crowded field of firms hoping to develop treatments for ...
statnews.com/2026/06/23/gene-editing-startup-serapha-bio-aatd/